VENTYX BIOSCIENCES INC (VTYX)
US92332V1070 - Common Stock
Taking everything into account, VTYX scores 2 out of 10 in our fundamental rating. VTYX was compared to 198 industry peers in the Pharmaceuticals industry. While VTYX has a great health rating, there are worries on its profitability. VTYX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year VTYX has reported negative net income.
In the past year VTYX has reported a negative cash flow from operations.
VTYX had negative earnings in each of the past 5 years.
VTYX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VTYX has a Return On Assets of -69.49%. This is in the lower half of the industry: VTYX underperforms 68.21% of its industry peers.
With a Return On Equity value of -79.11%, VTYX perfoms like the industry average, outperforming 44.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.49% | ||
| ROE | -79.11% | ||
| ROIC | N/A |
ROA(3y)-42.65%
ROA(5y)-3131.26%
ROE(3y)-46.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VTYX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for VTYX has been increased compared to 1 year ago.
There is no outstanding debt for VTYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VTYX has an Altman-Z score of 1.38. This is a bad value and indicates that VTYX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.38, VTYX is in the better half of the industry, outperforming 65.13% of the companies in the same industry.
There is no outstanding debt for VTYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.38 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
VTYX has a Current Ratio of 11.87. This indicates that VTYX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 11.87, VTYX belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
VTYX has a Quick Ratio of 11.87. This indicates that VTYX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.87, VTYX belongs to the top of the industry, outperforming 87.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.87 | ||
| Quick Ratio | 11.87 |
3. Growth
3.1 Past
VTYX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.98%.
EPS 1Y (TTM)-60.98%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-27.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 14.50% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.47%
EPS Next 2Y9.52%
EPS Next 3Y14.2%
EPS Next 5Y14.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VTYX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTYX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VTYX's earnings are expected to grow with 14.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.52%
EPS Next 3Y14.2%
5. Dividend
5.1 Amount
No dividends for VTYX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VENTYX BIOSCIENCES INC
NASDAQ:VTYX (4/26/2024, 7:23:26 PM)
After market: 3.94 +0.01 (+0.25%)3.93
-0.13 (-3.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap276.79M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.49% | ||
| ROE | -79.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.87 | ||
| Quick Ratio | 11.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-60.98%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y17.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y